Department of Retina and Vitreous Services, Aravind Eye Hospital, Madurai, Tamil Nadu, India.
Department of Medical Retina, NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.
Indian J Ophthalmol. 2021 Nov;69(11):3156-3164. doi: 10.4103/ijo.IJO_496_21.
There is an exponential rise in the prevalence of diabetes mellitus (DM) in India. Ideally all people with DM should be periodically screening for diabetic retinopathy (DR) but is not practical with current infrastructure. An alternate strategy is to identify high-risk individuals with vision-threatening diabetic retinopathy (VTDR) for priority screening and treatment.
We reanalyzed four population-based studies, conducted in South India between 2001 and 2010, and reclassified individuals above 40 years into known and newly diagnosed diabetes. Multiple regression analysis was done to identify risk factors in people with known and new DM.
The prevalence of DR in 44,599 subjects aged ≥40 years was 14.8% (18.4 and 4.7% in known and new DM, respectively), and the prevalence of VTDR was 5.1%. Higher risk factors of VTDR were older age >50 years, diabetes duration >5 years, and systolic blood pressure >140 mm Hg. Targeted screening of people with diabetes using high-risk criteria obtained from this study was able to detect 93.5% of all individuals with VTDR.
In a limited resource country like India, a high-risk group-based targeted screening of individuals with DM could be prioritized while continuing the current opportunistic screening till India adopts universal screening of all people with DM.
印度的糖尿病(DM)患病率呈指数级增长。理想情况下,所有 DM 患者都应定期筛查糖尿病视网膜病变(DR),但考虑到目前的基础设施,这并不现实。另一种策略是确定有威胁视力的糖尿病视网膜病变(VTDR)风险的高危人群,以便进行优先筛查和治疗。
我们重新分析了 2001 年至 2010 年间在印度南部进行的四项基于人群的研究,并将 40 岁以上的人群重新分类为已知和新诊断的糖尿病患者。采用多元回归分析确定已知和新发 DM 患者的危险因素。
在 44599 名年龄≥40 岁的受试者中,DR 的患病率为 14.8%(已知和新发 DM 分别为 18.4%和 4.7%),VTDR 的患病率为 5.1%。VTDR 的更高危险因素是年龄>50 岁、糖尿病病程>5 年和收缩压>140mmHg。使用本研究中获得的高危标准对糖尿病患者进行有针对性的筛查,可以检测到所有 VTDR 患者的 93.5%。
在印度这样一个资源有限的国家,可以对有糖尿病的高危人群进行有针对性的筛查,同时继续进行当前的机会性筛查,直到印度对所有糖尿病患者进行普遍筛查。